AstraZeneca Plc (NASDAQ:AZN) on Monday released topline data from the DESTINY-Breast09 Phase 3 trial of Enhertu (5.4mg/kg) either alone or in combination with pertuzumab versus standard of care THP (a taxane [docetaxel or paclitaxel], trastuzumab, and pertuzumab) as a first-line treatment in patients with HER2-positive metastatic breast cancer.

High-level results from a planned interim analysis showed Enhertu pertuzumab combination demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to THP.

Also Read: European Drug Regulator Approves AstraZeneca’s Two Flagship Cancer Drugs For Breast And Lung Cancer Settings

The PFS improvement was seen across all pre-specified patient subgroups with Enhertu in combination with pertuzumab.

The key secondary endpoint of overall survival (OS) was not mature at this planned interim analysis; however, interim OS data showed an early trend favoring the Enhertu combination compared with THP.

The second arm assessing Enhertu monotherapy versus THP remains blinded to patients and investigators and will continue to the final PFS analysis.

HER2-positive metastatic breast cancer is an aggressive disease driven by overexpression or amplification of HER2, affecting 15-20% of patients with metastatic breast cancer.

While HER2-targeted therapies have improved outcomes, prognosis remains poor, with most patients experiencing disease progression within two years of 1st-line treatment with THP, which has been the standard of care for more than a decade.

Further, approximately one in three patients never go on to receive treatment following 1st-line therapy due to disease progression or death.

The safety profile of Enhertu in combination with pertuzumab was consistent with the known profiles of each therapy.

Enhertu is a specifically engineered HER2-directed DXd antibody-drug conjugate (ADC) discovered by Daiichi Sankyo (OTC:DSNKY) (OTC:DSKYF) and being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.

Data from the combination arm of DESTINY-Breast09 will be presented at an upcoming medical meeting and shared with regulatory authorities.

Enhertu is already approved in more than 75 countries as the 2nd-line treatment for patients with HER2-positive breast cancer based on the results from the DESTINY-Breast03 trial.

In January, the U.S. Food and Drug Administration (FDA) approved Enhertu for adult patients with breast cancer that has progressed on one or more endocrine therapies in the metastatic setting.

The FDA granted the approval after securing Priority Review and Breakthrough Therapy Designation. It was based on results from the DESTINY-Breast06 Phase 3 trial.

Price Action: AZN stock is up 1.05% at $68.30 during the premarket session at the last check Monday.

Read Next:

• Tractor Supply Earnings Outlook Brightens With 2025 Profit Growth Potential, Says Analyst

Photo by Piotr Swat Shutterstock

UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.

Get the latest stock analysis from Benzinga?

• ASTRAZENECA (AZN): Free Stock Analysis Report

This article AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients originally appeared on Benzinga.com

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.